Leading Companies - Immune Checkpoint Inhibitors Industry

The introduction of innovative immune checkpoint inhibitors with fewer side effects is driving the growth of the worldwide immune checkpoint inhibitors market. Increased regulatory approval of Immune Checkpoint Inhibitors is projected to fuel the global immune checkpoint market. The Food and Drug Administration (FDA) authorised a combination of two immunotherapy medications for the treatment of certain persons with advanced melanoma on April 6, 2022. The combination will be marketed as Opdualag and will consist of relatlimab and nivolumab (Opdivo). Both medications are immune checkpoint inhibitors, which target proteins known as checkpoints. It aids in preventing the immune system from forming a powerful reaction to cancer cells. The high cost of immuno-oncology medicines, which is inaccessible to the poor and medium class people, is one of the primary reasons impeding the growth of the worldwide immune checkpoint inhibitors market.

According to Coherent Market Insights, The global Immune Checkpoint Inhibitors Market  is estimated to be valued at US$ 1,444.7 million in 2022 and is expected to exhibit a CAGR of 13.2% during the forecast period (2022-2030). Some of the companies highlighted by Coherent Market Insights are:

Major Players in the Immune Checkpoint Inhibitors Industry:

Bristol-Myers Squibb Company

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company was founded in 1887 and is headquartered in New York, New York. In January 2022, Sanofi-aventisand Bristol-Myers Squibb Company, announced that the U.S. Food and Drug Administration (FDA) had approved the supplemental new drug application (sNDA) for the antiplatelet agent PLAVIX(R) (clopidogrel bisulfate) to reduce the rate of death from any cause and the rate of a combined endpoint of re-infarction, stroke or death in patients with acute ST-segment elevation myocardial infarction (STEMI).

Merck & Co., Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

F. Hoffmann-La Roche AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, and internationally.  It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD). Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.

AstraZeneca Plc.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.  The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.  

Novartis International AG

The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. In January 2020, Novartis AG announced that it had completed acquisition of The Medicines Company, a pharmaceutical company. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol.

ImmunOs Therapeutics AG

The company is Developer of novel human immunomodulatory proteins and drugs designed to treat cancer and autoimmune diseases. The company's drugs use proteins that have direct anti-tumor effects that remodel the tumor microenvironment and enhance the efficacy of existing immunotherapies, enabling healthcare providers to treat their patients and improve their lives. The company was founded in 2014, headquartered in Switzerland.

Immutep Ltd.

Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. Immutep Limited was incorporated in 1987 and is headquartered in Sydney, Australia. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma.

NewLink Genetics Corporation

NewLink Genetics is a biopharmaceutical company focused on discovering, developing, and commercializing novel immuno-oncology products to improve the lives of patients with cancer. In Sep 1, 2019 Lumos Pharma acquired NewLink Genetics. The company was founded in 1999, headquartered in U.S.

*Definition-

Immune checkpoint inhibitors are classified as biologic therapeutic medicines. Prior to bringing a biologic product to market, biologic firms must get FDA clearance in the same way that pharmaceuticals do.